The evolving role of inotuzumab ozogamicin in the treatment of pediatric & older patients with ALL

The evolving role of inotuzumab ozogamicin in the treatment of pediatric & older patients with ALLПодробнее

What is the role of inotuzumab ozogamicin in ALLПодробнее

Improving adult ALL treatment: pediatric regimens & adding inotuzumabПодробнее

Phase II trial of inotuzumab ozogamicin to treat MRD+ B-ALLПодробнее

Elderly ALL advances: inotuzumab ozogamicin plus mini-hyper-CVDПодробнее

Phase II study of inotuzumab ozogamicin in MRD+ B-ALLПодробнее

Inotuzumab ozogamicin for the treatment of elderly acute lymphoblastic leukemiaПодробнее

When to Use Inotuzumab Ozogamicin for Adult ALLПодробнее

Inotuzumab ozogamicin for treating pediatric R/R ALLПодробнее

Inotuzumab as a potential treatment for elderly patients with ALLПодробнее

Novel ALL treatment strategies: inotuzumab ozogamicinПодробнее

Challenges and recent advances for pediatric ALLПодробнее

Blinatumomab and inotuzumab in children with R/R B-ALLПодробнее

Dr. Brammer on Data With Inotuzumab Ozogamicin in ALLПодробнее

Inotuzumab ozogamicin for MRD-positive B-ALLПодробнее

Pediatric leukemia at ASCO 2023Подробнее

Emerging novel approaches for ALL: inotuzumab ozogamicinПодробнее

Choosing between inotuzumab ozogamicin and blinatumomab in patients with R/R ALLПодробнее

Treatment Advances for Acute Lymphoblastic Leukemia (ALL) In Children and AdultsПодробнее

The future of inotuzumab therapy for ALLПодробнее